• Vaderis Therapeutics closed an oversubscribed USD 152 million Series B private placement to fund operations through potential U.S. approval of engasertib.
• Financing co-led by Goldman Sachs Alternatives, TCGX; included Medicxi, Droia Ventures, Omega Funds, EQT Life Sciences, Perceptive Advisors.
• Company launched HEROIC, a global Phase 3, randomized, double-blind, placebo-controlled trial of once-daily oral engasertib in moderate-to-severe HHT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Droia Ventures published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.